Physician profile
Crystal E Meyer
NPI 1841548161
$2,855.97
in general payments reported to CMS, 2019-2025
14 companies · $647 in 2025
The $647 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $404 · 2023: $1,116 · 2024: $402 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $800 · Food and Beverage: $770 · Education: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $800.00 |
| Food and Beverage | $769.51 |
| Education | $595.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,352.88 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $1,105.53 | 2021-2025 | Ilumya |
| Abbvie INC. | $78.97 | 2021-2025 | |
| Ucb, INC. | $47.82 | 2022-2023 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $43.06 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $40.83 | 2021-2022 | |
| Genzyme Corporation | $34.91 | 2022 | |
| Galderma Laboratories, L.P. | $30.30 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $28.75 | 2024-2025 | Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $25.70 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.77 | 2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $17.77 | 2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $16.08 | 2021 | |
| Dermavant Sciences, INC. | $13.60 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.